A 2003 study demonstrated that serum HE4 protein is detectable via double-determinant immunoassay and is an ovarian cancer biomarker with sensitivity and specificity comparable to that of CA125, the clinical “gold standard,” but with the likely advantage of lower false-positive rates in patients with benign disease [4]. This evidence concerns the gene WFDC2 and ovarian cancer.